Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varenicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 10/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 10/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 3/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 3/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRNG | P07510 | 1/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 1/20 | 1.00 |
| ▸ | CHRNA5 | P30532 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | CHRND | Q07001 | 1/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varenicline SCHEMBL137144 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL14003841 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL5959022 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29363551 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29710884 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL20553851 | 0.98 | CHRNB2 (0.96) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL31413921 | 0.98 | CHRNB4 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL23510345 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL20553574 | 0.87 | CHRNB2 (0.75) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL22323984 | 0.84 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569498-B2 | Methods and compositions for the prevention and treatment of ischemia reperfusion injury and infection | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2026-03-10 | — | — | US | claimed |
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | claimed |
| WO-2025040605-A1 | OPHTHALMOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR FOR TOPICAL ADMINISTRATION TO THE EYE FOR PREVENTING OR TREATING INFLAMMATION OF THE EYE | URSAPHARM ARZNEIMITTEL GMBH (DE) | 2025-02-27 | — | — | WO | claimed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | claimed |
| CN-119212689-A | Nicotinic acetylcholine receptor antagonists/blockers for increasing dopamine | 张燕峰 | 2024-12-27 | — | — | CN | claimed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | claimed |
| US-20220249508-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2022-08-11 | — | — | US | claimed |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | claimed |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | claimed |
| US-20210077478-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-03-18 | — | — | US | claimed |
| EP-2945633-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| EP-2945637-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| EP-2945626-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS PHARMA AG (CH) | 2015-11-05 | — | — | US | claimed |
| WO-2014111751-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| WO-2014111837-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| WO-2014111838-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| EP-2101763-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LAB (US) | 2012-07-18 | — | — | EP | claimed |
| US-20110274628-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. | 2011-11-10 | — | — | US | claimed |
| US-20260107973-A1 | AEROSOL-MODIFYING ADDITIVE COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107967-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108466-A1 | VARENICLINE FORMULATIONS | PFIZER (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107969-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107972-A1 | AEROSOL GENERATING GEL MATERIAL COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107971-A1 | AEROSOL GENERATING MATERIAL IN DISCRETE PORTIONS COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12569498-B2 | Methods and compositions for the prevention and treatment of ischemia reperfusion injury and infection | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260060287-A1 | AEROSOLIZABLE COMPOSITION INCLUDING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250302845-A1 | SELECTIVE DOPAMINE INCREASE | SOBRERA PHARMA AB (SE) | 2025-10-02 | — | — | US | disclosed |
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | disclosed |
| US-20250134904-A1 | SOLID PHARMACEUTICAL FORMULATIONS OF VARENICLINE | MEDICHEM, S.A. (ES) | 2025-05-01 | — | — | US | disclosed |
| EP-4522176-A1 | SELECTIVE DOPAMINE INCREASE | Sobrera Pharma AB (SE) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025040605-A1 | OPHTHALMOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR FOR TOPICAL ADMINISTRATION TO THE EYE FOR PREVENTING OR TREATING INFLAMMATION OF THE EYE | URSAPHARM ARZNEIMITTEL GMBH (DE) | 2025-02-27 | — | — | WO | disclosed |
| US-20250041232-A1 | MICROSPHERES COMPRISING HIGH-DOSE VARENICLINE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AULBIO CO., LTD. (KR) | 2025-02-06 | — | — | US | disclosed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212689-A | Nicotinic acetylcholine receptor antagonists/blockers for increasing dopamine | 张燕峰 | 2024-12-27 | — | — | CN | disclosed |
| US-20240299406-A1 | NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR PARTIAL AGONISTS AS THERAPEUTICS FOR CHRONIC TINNITUS | BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY | 2024-09-12 | — | — | US | disclosed |
| US-20240238375-A1 | AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF | Oyster Point Pharma, Inc. | 2024-07-18 | — | — | US | disclosed |
| CN-117883380-A | Transdermal emulsion for treating xerophthalmia | 首都医科大学附属北京同仁医院 | 2024-04-16 | — | — | CN | disclosed |
| US-11918588-B2 | Neuronal nicotinic acetylcholine receptor partial agonists as therapeutics for chronic tinnitus | BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117298073-B | Transdermal drug delivery pharmaceutical composition for treating xerophthalmia | 首都医科大学附属北京同仁医院 | 2024-02-20 | — | — | CN | disclosed |
| CN-117462557-A | Application of valicarb in preparation of antibiotic reinforcing agent | 大连医科大学附属第一医院 | 2024-01-30 | — | — | CN | disclosed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117298073-A | Transdermal drug delivery pharmaceutical composition for treating xerophthalmia | 首都医科大学附属北京同仁医院 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023219548-A1 | SELECTIVE DOPAMINE INCREASE | SOBRERA PHARMA AB (SE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023205249-A1 | NICOTINE AND NICOTINIC AGONIST COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PANCREATITIS AND METHODS OF USING SAME | DUKE UNIVERSITY (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | ENDO OPERATIONS LIMITED (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | ENDO OPERATIONS LIMITED (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | ENDO OPERATIONS LIMITED (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| EP-4241775-A1 | TABLET COMPRISING VARENICLINE AND PROCESS OF PREPARATION THEREOF | Par Pharmaceutical, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4241775-A1 | TABLET COMPRISING VARENICLINE AND PROCESS OF PREPARATION THEREOF | Par Pharmaceutical, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116725967-A | Valicarb isopropyl compound and process for producing the same | 帕尔制药公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230181577-A1 | STABLE COMPOSITIONS OF VARENICLINE | MANKIND PHARMA LTD. (IN) | 2023-06-15 | — | — | US | disclosed |
| US-20230181577-A1 | STABLE COMPOSITIONS OF VARENICLINE | MANKIND PHARMA LTD. (IN) | 2023-06-15 | — | — | US | disclosed |
| US-20230181577-A1 | STABLE COMPOSITIONS OF VARENICLINE | MANKIND PHARMA LTD. (IN) | 2023-06-15 | — | — | US | disclosed |
| WO-2023085503-A1 | MICROSPHERES COMPRISING HIGH-DOSE VARENICLINE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 아울바이오 | 2023-05-19 | — | — | WO | disclosed |
| US-20230148226-A1 | COMPOSITIONS OF STABLE FORMULATIONS OF VARENICLINE SALT OR BASE FORM WITH CONTROL ON NITROSO IMPURITIES | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-05-11 | — | — | US | disclosed |
| WO-2023076282-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF VARENICLINE WITH CONTROL ON NITROSO IMPURITIES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-4169516-A1 | PREVENTION OF THE CONVERSION OF PHARMACEUTICAL AGENTS INTO TOXIC N-NITROSAMINE COMPOUNDS | Alfred E. Tiefenbacher (GmbH & Co. KG) (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-20230094827-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | POVIVA CORP | 2023-03-30 | — | — | US | disclosed |
| US-11602537-B2 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-11596597-B2 | Depot formulation | CIPLA LIMITED (IN) | 2023-03-07 | — | — | US | disclosed |
| WO-2023275413-A2 | SOLID PHARMACEUTICAL FORMULATIONS OF VARENICLINE | MEDICHEM, S.A. (ES) | 2023-01-05 | — | — | WO | disclosed |
| US-20220401453-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ISCHEMIA REPERFUSION INJURY AND INFECTION | CHILDREN'S NATIONAL MEDICAL CENTER | 2022-12-22 | — | — | US | disclosed |
| US-20220401453-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ISCHEMIA REPERFUSION INJURY AND INFECTION | CHILDREN'S NATIONAL MEDICAL CENTER | 2022-12-22 | — | — | US | disclosed |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| US-20220249508-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2022-08-11 | — | — | US | disclosed |
| EP-3785702-B1 | MICROPARTICULATE VARENICLINE CITRATE | TIEFENBACHER ALFRED E GMBH & CO KG (DE) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022147189-A1 | VARENICLINE PRODRUGS | ANTARES PHARMA, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | disclosed |
| CN-114689778-A | Method for measuring related substances of varenicline tartrate by high performance liquid chromatography | 江苏嘉逸医药有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114689762-A | Method for detecting aldehyde genotoxic impurities in high-purity valnemulin tartrate raw material | 江苏嘉逸医药有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| CN-113185513-B | Method for synthesizing Vanillan | 苏州富德兆丰生化科技有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20220160731-A1 | COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE AGENTS AND BILE SALTS | POVIVA CORP | 2022-05-26 | — | — | US | disclosed |
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| CN-114349701-A | Preparation method of varenicline tartrate intermediate | 江苏豪森药业集团有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3972582-A1 | COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE AGENTS AND BILE SALTS | Poviva Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972584-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | Poviva Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220088028-A1 | NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR PARTIAL AGONISTS AS THERAPEUTICS FOR CHRONIC TINNITUS | BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY | 2022-03-24 | — | — | US | disclosed |
| US-11266658-B2 | Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration | CTC BIO, INC. (KR) | 2022-03-08 | — | — | US | disclosed |
| WO-2022035434-A1 | COCRYSTAL OF VARENICLINE AND OXALIC ACID, PHARMACEUTICAL COMPOSITION THEREOF, AND METHODS OF USE THEREOF | ALMATICA PHARMA LLC (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022035434-A1 | COCRYSTAL OF VARENICLINE AND OXALIC ACID, PHARMACEUTICAL COMPOSITION THEREOF, AND METHODS OF USE THEREOF | ALMATICA PHARMA LLC (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2021259396-A2 | NITROSAMINE IMPURITY, VARENICLINE PHARMACEUTICAL COMPOSITION CAPABLE OF REDUCING GENERATION OF NITROSAMINE IMPURITIES AND PREPARATION AND USE THEREOF | 威智医药有限公司 | 2021-12-30 | — | — | WO | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20210206831-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | HOWARD HUGHES MEDICAL INSTITUTE | 2021-07-08 | — | — | US | disclosed |
| EP-2945633-B1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-06-30 | — | — | EP | disclosed |
| US-11040983-B1 | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof | ALMATICA PHARMA LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040983-B1 | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof | ALMATICA PHARMA LLC (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3829562-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | Amygdala Neurosciences, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20210154136-A1 | DEPOT FORMULATION | CIPLA LIMITED (IN) | 2021-05-27 | — | — | US | disclosed |
| US-20210145841-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| US-20210145844-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| EP-3810135-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Poviva Corp. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10961296-B2 | Modified ligand-gated ion channels and methods of use | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210077478-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-03-18 | — | — | US | disclosed |
| EP-2945637-B1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-03-10 | — | — | EP | disclosed |
| EP-3785702-A1 | MICROPARTICULATE VARENICLINE CITRATE | Alfred E. Tiefenbacher (GmbH & Co. KG) (DE) | 2021-03-03 | — | — | EP | disclosed |
| EP-3780976-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781163-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10912734-B2 | Depot formulation | CIPLA LIMITED (IN) | 2021-02-09 | — | — | US | disclosed |
| EP-3756653-A1 | MICROPARTICULATE VARENICLINE CITRATE | Alfred E. Tiefenbacher (GmbH & Co. KG) (DE) | 2020-12-30 | — | — | EP | disclosed |
| WO-2020236802-A1 | COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE AGENTS AND BILE SALTS | Poviva Corp. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236798-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | Poviva Corp. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20200276113-A1 | TASTE-MASKED AND ORALLY ADMINISTERED PHARMACEUTICAL PREPARATION CONTAINING VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CTC BIO, INC. (KR) | 2020-09-03 | — | — | US | disclosed |
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2020163588-A1 | NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR PARTIAL AGONISTS AS THERAPEUTICS FOR CHRONIC TINNITUS | BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-2776030-B1 | 2,5-DISUBSTITUTED-PYRIDYL NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20200061078-A1 | PREPARATION, COMPRISING INCLUSION COMPLEX OF VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR ORAL ADMINISTRATION | CTC BIO, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| WO-2020023792-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023792-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20190350844-A1 | DEPOT FORMULATION | CIPLA LIMITED (IN) | 2019-11-21 | — | — | US | disclosed |
| WO-2019204502-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019202396-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190169264-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | HOWARD HUGHES MEDICAL INSTITUTE | 2019-06-06 | — | — | US | disclosed |
| WO-2019025521-A1 | NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE | MEDICHEM, S.A. (ES) | 2019-02-07 | — | — | WO | disclosed |
| EP-3400964-A1 | TASTE-MASKED AND ORALLY ADMINISTERED PHARMACEUTICAL PREPARATION CONTAINING VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CTC Bio, Inc. (KR) | 2018-11-14 | — | — | EP | disclosed |
| WO-2018163190-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF VARENICLINE AND SALT THEREOF | JUBILANT GENERICS LIMITED (FORMERLY A DIVISION OF JUBILANT LIFESCIENCES LIMITED) (IN) | 2018-09-13 | — | — | WO | disclosed |
| US-9937168-B2 | Nicotine-containing pharmaceutical compositions | NICONOVUM USA, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-3284467-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | Niconovum USA, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| US-20170348294-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-2931315-B1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-9828642-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-20170326138-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| EP-2840146-B1 | METHOD TO PREDICT THE SAFETY OF THE TREATMENT WITH A NICOTINIC CHOLINERGIC RECEPTOR AGONIST | GENETRACER BIOTECH S L (ES) | 2017-07-19 | — | — | EP | disclosed |
| EP-2837632-B1 | Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases | LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO LTD (CN) | 2016-05-18 | — | — | EP | disclosed |
| EP-2959902-A1 | USE OF AZABICYCLOALKYL DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | Novartis AG (CH) | 2015-12-30 | — | — | EP | disclosed |
| EP-2945633-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | disclosed |
| EP-2945626-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | Novartis AG (CH) | 2015-11-25 | — | — | EP | disclosed |
| EP-2945637-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | disclosed |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS PHARMA AG (CH) | 2015-11-05 | — | — | US | disclosed |
| EP-2931315-A2 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | Novartis AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-20150275303-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2015-10-01 | — | — | US | disclosed |
| US-9090623-B2 | Compound JK12A and preparation thereof | LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD. (CN) | 2015-07-28 | — | — | US | disclosed |
| US-20150094220-A1 | METHOD TO PREDICT THE SAFETY OF THE TREATMENT WITH A NICOTINIC CHOLINERGIC RECEPTOR AGONIST | GENETRACER BIOTECH S.L. (ES) | 2015-04-02 | — | — | US | disclosed |
| US-20150094220-A1 | METHOD TO PREDICT THE SAFETY OF THE TREATMENT WITH A NICOTINIC CHOLINERGIC RECEPTOR AGONIST | GENETRACER BIOTECH S.L. (ES) | 2015-04-02 | — | — | US | disclosed |
| US-20150094220-A1 | METHOD TO PREDICT THE SAFETY OF THE TREATMENT WITH A NICOTINIC CHOLINERGIC RECEPTOR AGONIST | GENETRACER BIOTECH S.L. (ES) | 2015-04-02 | — | — | US | disclosed |
| US-20150065708-A1 | COMPOUND JK12A AND PREPARATION THEREOF | LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD. (CN) | 2015-03-05 | — | — | US | disclosed |
| EP-2840146-A1 | METHOD TO PREDICT THE SAFETY OF THE TREATMENT WITH A NICOTINIC CHOLINERGIC RECEPTOR AGONIST | Genetracer Biotech S.L. (ES) | 2015-02-25 | — | — | EP | disclosed |
| EP-2837632-A1 | COMPOUND JK12A AND PREPARATION THEREOF | Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. (CN) | 2015-02-18 | — | — | EP | disclosed |
| US-8933024-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-01-13 | — | — | US | disclosed |
| US-8933024-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-01-13 | — | — | US | disclosed |
| WO-2014176460-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | CHAU DAVID T (US) | 2014-10-30 | — | — | WO | disclosed |
| EP-2768507-A2 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | Novartis AG (CH) | 2014-08-27 | — | — | EP | disclosed |
| US-20140228398-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| WO-2014111838-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014111751-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014111837-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014091388-A2 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| US-20140128606-A1 | ANTIPRURITIC AGENT | TORAY INDUSTRIES, INC. (JP) | 2014-05-08 | — | — | US | disclosed |
| EP-2727604-A1 | ANTIPRURITIC AGENT | Toray Industries, Inc. (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20140060552-A1 | METHODS AND DEVICES FOR DELIVERY AND MONITORING OF TOBACCO, NICOTINE, OR OTHER SUBSTANCES | PLOOM, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2685977-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | Novartis AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| EP-2667862-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-20130289019-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | Amazing Grace, Inc. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130231388-A1 | (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT | SANOFI (FR) | 2013-09-05 | — | — | US | disclosed |
| US-20130231388-A1 | (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT | SANOFI (FR) | 2013-09-05 | — | — | US | disclosed |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130142821-A1 | Hapten-Carrier Conjugates and Uses Thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2013-06-06 | — | — | US | disclosed |
| US-8440825-B2 | Fumaric acid salt of varenicline | MEDICHEM S.A. (ES) | 2013-05-14 | — | — | US | disclosed |
| US-8440825-B2 | Fumaric acid salt of varenicline | MEDICHEM S.A. (ES) | 2013-05-14 | — | — | US | disclosed |
| US-8440825-B2 | Fumaric acid salt of varenicline | MEDICHEM S.A. (ES) | 2013-05-14 | — | — | US | disclosed |
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2013-04-25 | — | — | US | disclosed |
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2013-04-25 | — | — | US | disclosed |
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2013-04-25 | — | — | US | disclosed |
| WO-2013057687-A2 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| EP-2581375-A2 | IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES | Medichem, S.A. (ES) | 2013-04-17 | — | — | EP | disclosed |
| EP-2581375-A2 | IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES | Medichem, S.A. (ES) | 2013-04-17 | — | — | EP | disclosed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | disclosed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | disclosed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | disclosed |
| EP-2545054-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | Actavis Group Ptc Ehf (IS) | 2013-01-16 | — | — | EP | disclosed |
| US-8314235-B2 | Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof | ACTAVIS GROUP PTC EHF (IS) | 2012-11-20 | — | — | US | disclosed |
| US-8314235-B2 | Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof | ACTAVIS GROUP PTC EHF (IS) | 2012-11-20 | — | — | US | disclosed |
| US-8314235-B2 | Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof | ACTAVIS GROUP PTC EHF (IS) | 2012-11-20 | — | — | US | disclosed |
| US-20120277433-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED QUINOXALINES | ALKEM LABORATORIES LIMITED (IN) | 2012-11-01 | — | — | US | disclosed |
| WO-2012127393-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012101060-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| EP-2480228-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | Novartis AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2101763-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LAB (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG | 2012-07-05 | — | — | US | disclosed |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | NOVARTIS AG | 2012-06-21 | — | — | US | disclosed |
| EP-2456438-A2 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-8178537-B2 | Solid state forms of varenicline salts and processes for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-05-15 | — | — | US | disclosed |
| US-20120093887-A1 | AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES | ACTAVIS GROUP PTC EHF (IS) | 2012-04-19 | — | — | US | disclosed |
| US-20120093887-A1 | AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES | ACTAVIS GROUP PTC EHF (IS) | 2012-04-19 | — | — | US | disclosed |
| US-20120093887-A1 | AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES | ACTAVIS GROUP PTC EHF (IS) | 2012-04-19 | — | — | US | disclosed |
| EP-2440187-A2 | AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES | Actavis Group PTC ehf. (IS) | 2012-04-18 | — | — | EP | disclosed |
| US-20120004239-A1 | Process for Preparing Quinoxaline Derivatives | MEDICHEM, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20120004239-A1 | Process for Preparing Quinoxaline Derivatives | MEDICHEM, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20120004239-A1 | Process for Preparing Quinoxaline Derivatives | MEDICHEM, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| WO-2011154586-A2 | IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES | MEDICHEM, S. A. (ES) | 2011-12-15 | — | — | WO | disclosed |
| EP-2392345-A2 | Hapten-carrier conjugates comprising virus like particles and uses thereof | Cytos Biotechnology AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20110274628-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. | 2011-11-10 | — | — | US | disclosed |
| WO-2011140431-A1 | VARENICLINE SALTS AND CRYSTAL FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-11-10 | — | — | WO | disclosed |
| US-8039620-B2 | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-10-18 | — | — | US | disclosed |
| US-8039620-B2 | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-10-18 | — | — | US | disclosed |
| US-20110237597-A1 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | UNIVERSITY OF SOUTH FLORIDA | 2011-09-29 | — | — | US | disclosed |
| WO-2011110954-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011110954-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | disclosed |
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | disclosed |
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | disclosed |
| EP-1909773-B1 | TRANSDERMAL SYSTEM FOR VARENICLINE | PFIZER PROD INC (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010023561-A9 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-08-04 | — | — | WO | disclosed |
| WO-2010023561-A9 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-08-04 | — | — | WO | disclosed |
| EP-2334679-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Actavis Group PTC EHF (IS) | 2011-06-22 | — | — | EP | disclosed |
| US-20110105750-A1 | Salts of a Pyrazino[2,3-h][3]Benzazepine Derivative | MEDICHEM, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105750-A1 | Salts of a Pyrazino[2,3-h][3]Benzazepine Derivative | MEDICHEM, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105750-A1 | Salts of a Pyrazino[2,3-h][3]Benzazepine Derivative | MEDICHEM, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110086086-A1 | TRANSDERMAL SYSTEM FOR VARENICLINE | PFIZER INC | 2011-04-14 | — | — | US | disclosed |
| US-20110086086-A1 | TRANSDERMAL SYSTEM FOR VARENICLINE | PFIZER INC | 2011-04-14 | — | — | US | disclosed |
| US-20110086086-A1 | TRANSDERMAL SYSTEM FOR VARENICLINE | PFIZER INC | 2011-04-14 | — | — | US | disclosed |
| WO-2011036167-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110064750-A1 | METHOD AND KIT FOR TREATING NICOTINE ADDICTION | NABI BIOPHARMACEUTICALS | 2011-03-17 | — | — | US | disclosed |
| EP-2268639-A2 | VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE | Teva Pharmaceutical Industries Ltd. (IL) | 2011-01-05 | — | — | EP | disclosed |
| US-20100324055-A1 | SOLID STATES FORMS OF VARENICLINE SALTS AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2010-12-23 | — | — | US | disclosed |
| EP-2262780-A2 | AMORPHOUS VARENICLINE TARTRATE | Dr. Reddy's Laboratories, Ltd. (IN) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010143070-A2 | AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES | ACTAVIS GROUP PTC EHF (IS) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143070-A2 | AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES | ACTAVIS GROUP PTC EHF (IS) | 2010-12-16 | — | — | WO | disclosed |
| EP-2260037-A2 | A POLYMORPHIC FORM OF A PYRAZINO [2,3-H] [3] BENZAZEPINE DERIVATIVE | Medichem, S.A. (ES) | 2010-12-15 | — | — | EP | disclosed |
| US-7771748-B2 | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | PFIZER INC (US) | 2010-08-10 | — | — | US | disclosed |
| WO-2009143347-A9 | VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-07-29 | — | — | WO | disclosed |
| WO-2009143347-A9 | VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-07-29 | — | — | WO | disclosed |
| EP-2204369-A1 | Process for preparing varenicline and intermediates for use therein | Medichem, S.A. (ES) | 2010-07-07 | — | — | EP | disclosed |
| EP-2204369-A1 | Process for preparing varenicline and intermediates for use therein | Medichem, S.A. (ES) | 2010-07-07 | — | — | EP | disclosed |
| US-20100062046-A1 | POLYMORPHS OF NICOTINIC INTERMEDIATES | ALLEN DOUGLAS J M | 2010-03-11 | — | — | US | disclosed |
| US-20100062046-A1 | POLYMORPHS OF NICOTINIC INTERMEDIATES | ALLEN DOUGLAS J M | 2010-03-11 | — | — | US | disclosed |
| WO-2010023561-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010023561-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-03-04 | — | — | WO | disclosed |
| US-20100048606-A1 | 10-Substituted Cytisine Derivatives and Methods of Use Thereof | Georgetown University Office of Technology Commercialization (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100010221-A1 | PROCESSES FOR PURIFYING VARENICLINE L-TARTRATE SALT AND PREPARING CRYSTALLINE FORMS OF VARENICLINE L-TARTRATE SALT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-01-14 | — | — | US | disclosed |
| US-20100004451-A1 | VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE | TEVA PHARMACEUTICALS USA, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20100004451-A1 | VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE | TEVA PHARMACEUTICALS USA, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20090318695-A1 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-24 | — | — | US | disclosed |
| US-20090318695-A1 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-24 | — | — | US | disclosed |
| US-20090318695-A1 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-24 | — | — | US | disclosed |
| WO-2009155403-A2 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155403-A2 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009101185-A3 | A POLYMORPHIC FORM OF A PYRAZINO [2, 3-H] [3] BENZAZEPINE DERIVATIVE | MEDICHEM, S.A. (ES) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009143347-A2 | VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143347-A2 | VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009131692-A1 | SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009109651-A1 | SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE | MEDICHEM, S.A. (ES) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109651-A1 | SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE | MEDICHEM, S.A. (ES) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111623-A2 | AMORPHOUS VARENICLINE TARTRATE | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111623-A2 | AMORPHOUS VARENICLINE TARTRATE | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-09-11 | — | — | WO | disclosed |
| US-20090215787-A1 | Preparations of new polymorphic forms of varenicline tartrate | MAI DE LTD. | 2009-08-27 | — | — | US | disclosed |
| US-20090215787-A1 | Preparations of new polymorphic forms of varenicline tartrate | MAI DE LTD. | 2009-08-27 | — | — | US | disclosed |
| WO-2009101185-A2 | A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE | MEDICHEM, S.A. (ES) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009065872-A2 | IMPROVED PROCESSES FOR THE SYNTHESIS OF VARENICLINE L-TARTRATE | MEDICHEM, S.A. (ES) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009034431-A2 | CONTROLLED-RELEASE DOSAGE FORMS FOR VARENICLINE | PFIZER INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009027786-A2 | MATRIX DOSAGE FORMS OF VARENICLINE | PFIZER INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-7452541-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20080275051-A1 | Preparation of High Purity Substituted Quinoxalines | BUSCH FRANK R | 2008-11-06 | — | — | US | disclosed |
| US-20080275051-A1 | Preparation of High Purity Substituted Quinoxalines | BUSCH FRANK R | 2008-11-06 | — | — | US | disclosed |
| EP-1866308-B1 | PREPARATION OF A HIGH PURITY SUBSTITUTED QUINOXALINE | PFIZER PROD INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1638971-B1 | PREPARATION OF SUBSTITUTED QUINOXALINES FROM THE DIANILINE WITH 2,3-DIHYDROXY-1,4-DIOXANE | PFIZER PROD INC (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1638971-B1 | PREPARATION OF SUBSTITUTED QUINOXALINES FROM THE DIANILINE WITH 2,3-DIHYDROXY-1,4-DIOXANE | PFIZER PROD INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080181933-A1 | Chewing Gum Compositions of Varenicline | PFIZER INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080181933-A1 | Chewing Gum Compositions of Varenicline | PFIZER INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080181933-A1 | Chewing Gum Compositions of Varenicline | PFIZER INC. | 2008-07-31 | — | — | US | disclosed |
| WO-2008060487-A2 | POLYMORPHS OF NICOTINIC INTERMEDIATES | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1909773-A1 | TRANSDERMAL SYSTEM FOR VARENICLINE | Pfizer Products Incorporated (US) | 2008-04-16 | — | — | EP | disclosed |
| CN-100370987-C | Tartrate salt of 5,8,14-triazatetracyclo [10,3,1,02,11.04,9]-hexzdeca-2(11),3,5,7,9-pentaene | PFIZER PROD INC (US) | 2008-02-27 | — | — | CN | disclosed |
| US-20080026059-A1 | Methods of Reducing Degradant Formation in Pharmaceutical Compositions of Varenicline | PFIZER INC | 2008-01-31 | — | — | US | disclosed |
| US-20080026059-A1 | Methods of Reducing Degradant Formation in Pharmaceutical Compositions of Varenicline | PFIZER INC | 2008-01-31 | — | — | US | disclosed |
| EP-1863442-A2 | CHEWING GUM COMPOSITIONS OF VARENICLINE | Pfizer Products Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1843769-A1 | FAST-DISINTEGRATING DOSAGE FORMS OF 5,8,14-TRIAZATETRACYCLO[10.3.1.02,11.04,9]-HEXADECA-2(11),3,5,7,9-PENTAENE | Pfizer Products Incorporated (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1843769-A1 | FAST-DISINTEGRATING DOSAGE FORMS OF 5,8,14-TRIAZATETRACYCLO[10.3.1.02,11.04,9]-HEXADECA-2(11),3,5,7,9-PENTAENE | Pfizer Products Incorporated (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007115092-A2 | 10-SUBSTITUTED CYTISINE DERIVATIVES AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007110730-A2 | VARENICLINE STANDARDS AND IMPURITY CONTROLS | PFIZER PRODUCTS INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070224690-A1 | VARENICLINE STANDARDS AND IMPURITY CONTROLS | PFIZER INC | 2007-09-27 | — | — | US | disclosed |
| US-20070224690-A1 | VARENICLINE STANDARDS AND IMPURITY CONTROLS | PFIZER INC | 2007-09-27 | — | — | US | disclosed |
| US-7265119-B2 | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | PFIZER INC (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265119-B2 | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | PFIZER INC (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265119-B2 | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | PFIZER INC (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070185327-A1 | Preparation of substituted quinoxalines | PFIZER INC | 2007-08-09 | — | — | US | disclosed |
| EP-1448235-B1 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF 5,8,14-TRIAZATETRACYCLO 10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE | PFIZER PROD INC (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1448235-B1 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF 5,8,14-TRIAZATETRACYCLO 10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE | PFIZER PROD INC (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2007012963-A1 | TRANSDERMAL SYSTEM FOR VARENICLINE | PFIZER PRODUCTS INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012963-A1 | TRANSDERMAL SYSTEM FOR VARENICLINE | PFIZER PRODUCTS INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| CN-1864663-A | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene | PFIZER (US) | 2006-11-22 | — | — | CN | disclosed |
| WO-2006100595-A2 | CHEWING GUM COMPOSITIONS OF VARENICLINE | PFIZER PRODUCTS INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006072832-A1 | FAST-DISINTEGRATING DOSAGE FORMS OF 5,8,14-TRIAZATETRACYCLO[10.3.1.02,11.04,9]-HEXADECA-2(11),3,5,7,9-PENTAENE | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072832-A1 | FAST-DISINTEGRATING DOSAGE FORMS OF 5,8,14-TRIAZATETRACYCLO[10.3.1.02,11.04,9]-HEXADECA-2(11),3,5,7,9-PENTAENE | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060084656-A1 | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline | PFIZER INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006040680-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL, BUCCAL, SUBLINGUAL AND PULMONARY DELIVERY OF VARENICLINE | PFIZER PRODUCTS INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079707-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| EP-1638971-A1 | PREPARATION OF SUBSTITUTED QUINOXALINES FROM THE DIANILINE WITH 2,3-DIHYDROXY-1,4-DIOXANE | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060057207-A1 | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| US-20060057207-A1 | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| US-20050281845-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-12-22 | — | — | US | disclosed |
| EP-1390366-B1 | THE CITRATE SALT OF 5,8,14,-TRIAZATETRACYCLO(10.3.1.02,11.04,9)-HEXADECA-2(11),3,5,7,9-PENTAENE | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1392307-B1 | TARTRATE SALTS OF 5,8,14-TRIAZATETRACYCLO[10.3.1.02,11.04,9]-HEXADECA-2(11),3,5,7,9-PENTAENE | PFIZER PROD INC (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1392307-B1 | TARTRATE SALTS OF 5,8,14-TRIAZATETRACYCLO[10.3.1.02,11.04,9]-HEXADECA-2(11),3,5,7,9-PENTAENE | PFIZER PROD INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6932971-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-08-23 | — | — | US | disclosed |
| US-20050148591-A1 | Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof | PFIZER INC | 2005-07-07 | — | — | US | disclosed |
| EP-1523334-A2 | HAPTEN-CARRIER CONJUGATES AND USES THEREOF | Cytos Biotechnology AG (CH) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004108725-A1 | PREPARATION OF SUBSTITUTED QUINOXALINES FROM THE DIANLINE WITH 2,3-DIHYDROXY-1,4-DIOXANE | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004103372-A1 | PHARMACEUTICAL COMPOSITIONS OF VARENICLINE | PFIZER PRODUCTS INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-6787549-B2 | FOR THERAPY OF INFLAMMATORY BOWEL DISEASE, ULCERATIVE COLITIS, PYODERMA GANGRENOSUM, CROHN'S DISEASE, IRRITABLE BOWEL SYNDROME, SPASTIC DYSTONIA, CHRONIC PAIN, ACUTE PAIN, CELIAC SPRUE, POUCHITIS, VASOCONSTRICTION, ANXIETY, PANIC DISORDER | PFIZER INC. | 2004-09-07 | — | — | US | disclosed |
| CN-1509174-A | 5,8, 14-triazatetracyclo [10.3.1.02，11.04，9]Tartrate salt of hexadeca-2 (11),3,5,7, 9-pentaene | �Ʒ� | 2004-06-30 | — | — | CN | disclosed |
| CN-1509288-A | 5,8, 14-triazatetracyclo [10.3.1.02，11.04，9]Citrate salt of hexadec-2 (11),3,5,7, 9-pentaene | �Ʒ� | 2004-06-30 | — | — | CN | disclosed |
| US-20040059094-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2004-03-25 | — | — | US | disclosed |
| EP-1392307-A1 | TARTRATE SALTS OF 5,8,14-TRIAZATETRACYCLO[10.3.1.02,11.04,9]-HEXADECA-2(11),3,5,7,9-PENTAENE | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1390366-A1 | THE CITRATE SALT OF 5,8,14,-TRIAZATETRACYCLO(10.3.1.02,11.04,9)-HEXADECA-2(11),3,5,7,9-PENTAENE | Pfizer Products Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004009116-A2 | HAPTEN-CARRIER CONJUGATES COMPRISING VIRUS LIKE PARTICLES AND USES THEREOF | CYTOS BIOTECHNOLOGY AG (CH) | 2004-01-29 | — | — | WO | disclosed |
| US-20030180360-A1 | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene | PFIZER INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003045437-A8 | PHARMACEUTICAL COMPOSITIONS OF 5,7,14-TRIAZATETRACYCLO[10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE | PFIZER PROD INC (US) | 2003-08-14 | — | — | WO | disclosed |
| US-6605610-B1 | Reducing nicotine addiction; treating neurological and psychological disorders | PFIZER INC | 2003-08-12 | — | — | US | disclosed |
| US-20030149091-A1 | Citrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003045437-A1 | PHARMACEUTICAL COMPOSITIONS OF 5,7,14-TRIAZATETRACYCLO[10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003045437-A1 | PHARMACEUTICAL COMPOSITIONS OF 5,7,14-TRIAZATETRACYCLO[10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002092089-A1 | TARTRATE SALTS OF 5,8,14-TRIAZATETRACYCLO {10.3.1.0?2,11.04,9¿}-HEXADECA-2(11),3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092089-A1 | TARTRATE SALTS OF 5,8,14-TRIAZATETRACYCLO {10.3.1.0?2,11.04,9¿}-HEXADECA-2(11),3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092597-A1 | THE CITRATE SALT OF 5, 8, 14-TRIAZATETRACYCLO(10.3.1.0?2,11.04.9¿)-HEXADECA-2.(11),3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092597-A1 | THE CITRATE SALT OF 5, 8, 14-TRIAZATETRACYCLO(10.3.1.0?2,11.04.9¿)-HEXADECA-2.(11),3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092089-A1 | TARTRATE SALTS OF 5,8,14-TRIAZATETRACYCLO {10.3.1.0?2,11.04,9¿}-HEXADECA-2(11),3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040983-B1 | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof | OTC, CYP2A7, CYP3A7 | CHRNB2 241/4885CHRNA4 230/4885CHRNB4 450/4885 |
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | CHRNB2 114/4885CHRNA4 167/4885CHRNB4 296/4885 |
| US-11266658-B2 | Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration | TAS2R7, CACNG7, CYP3A7 | CHRNB2 292/4885CHRNA4 283/4885CHRNB4 351/4885 |
| US-20110105750-A1 | Salts of a Pyrazino[2,3-h][3]Benzazepine Derivative | GRIN2C, SLC16A7, ME2 | CHRNB2 1626/4885CHRNA4 1129/4885CHRNB4 2319/4885 |
| US-20150275303-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNB2 9/4885CHRNA4 2/4885CHRNB4 5/4885 |
| US-20200276113-A1 | TASTE-MASKED AND ORALLY ADMINISTERED PHARMACEUTICAL PREPARATION CONTAINING VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAS2R7, TAS2R5, TAS2R10 | CHRNB2 156/4885CHRNA4 138/4885CHRNB4 220/4885 |
| US-20260107971-A1 | AEROSOL GENERATING MATERIAL IN DISCRETE PORTIONS COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, CHRM1 | CHRNB2 504/4885CHRNA4 195/4885CHRNB4 469/4885 |
| US-20050148591-A1 | Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof | SLC10A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP8B1 | CHRNB2 3018/4885CHRNA4 2276/4885CHRNB4 2816/4885 |
| US-20250041232-A1 | MICROSPHERES COMPRISING HIGH-DOSE VARENICLINE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PDE7A, CHRNA7, CHRM5 | CHRNB2 90/4885CHRNA4 116/4885CHRNB4 209/4885 |
| US-20100048606-A1 | 10-Substituted Cytisine Derivatives and Methods of Use Thereof | CHRNA10, CHRNA5, CHRNA1 | CHRNB2 20/4885CHRNA4 12/4885CHRNB4 21/4885 |
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA1, CHRNA5 | CHRNB2 16/4885CHRNA4 4/4885CHRNB4 14/4885 |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB2 88/4885CHRNA4 82/4885CHRNB4 101/4885 |
| US-20210206831-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | GRIK4, GRIK2, GRIK5 | CHRNB2 83/4885CHRNA4 64/4885CHRNB4 78/4885 |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | ALK, EXOSC4, EXOSC9 | CHRNB2 755/4885CHRNA4 472/4885CHRNB4 792/4885 |
| US-20100004451-A1 | VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE | VARS1, COMT, HDLBP | CHRNB2 59/4885CHRNA4 47/4885CHRNB4 71/4885 |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNB2 9/4885CHRNA4 2/4885CHRNB4 5/4885 |
| US-20220249508-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB2 49/4885CHRNA4 41/4885CHRNB4 43/4885 |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | CHRNB2 114/4885CHRNA4 167/4885CHRNB4 296/4885 |
| US-20170348294-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA5 | CHRNB2 16/4885CHRNA4 4/4885CHRNB4 14/4885 |
| US-20140228398-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | CHRNA5, GRM5, CHRNA7 | CHRNB2 31/4885CHRNA4 10/4885CHRNB4 30/4885 |
| US-20100324055-A1 | SOLID STATES FORMS OF VARENICLINE SALTS AND PROCESSES FOR PREPARATION THEREOF | SPIN2B, CACNA1S, VARS1 | CHRNB2 142/4885CHRNA4 72/4885CHRNB4 155/4885 |
| US-20230181577-A1 | STABLE COMPOSITIONS OF VARENICLINE | CHRNA7, CHRNA9, CHRNA5 | CHRNB2 15/4885CHRNA4 14/4885CHRNB4 24/4885 |
| US-20060084656-A1 | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline | CHRNA7, CYP3A7, ATXN10 | CHRNB2 51/4885CHRNA4 77/4885CHRNB4 92/4885 |
| US-20210145844-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | CHRNA2, ALDH2, ALDH1A1 | CHRNB2 4/4885CHRNA4 16/4885CHRNB4 28/4885 |
| US-20260108466-A1 | VARENICLINE FORMULATIONS | CACNA1I, CACNG7, CACNA1G | CHRNB2 96/4885CHRNA4 74/4885CHRNB4 130/4885 |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB2 49/4885CHRNA4 41/4885CHRNB4 43/4885 |
| US-20250134904-A1 | SOLID PHARMACEUTICAL FORMULATIONS OF VARENICLINE | SLC6A2, CACNA1S, NOX4 | CHRNB2 130/4885CHRNA4 104/4885CHRNB4 143/4885 |
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | PDE7A, CHRNA7, HTR7 | CHRNB2 52/4885CHRNA4 48/4885CHRNB4 102/4885 |
| US-20260107967-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EXOSC4, CHRM3 | CHRNB2 319/4885CHRNA4 292/4885CHRNB4 357/4885 |
| US-11596597-B2 | Depot formulation | CHRNA7, CHRNA1, CHRNB1 | CHRNB2 25/4885CHRNA4 14/4885CHRNB4 28/4885 |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | LIPC, PNLIP, LIPA | CHRNB2 4527/4885CHRNA4 4395/4885CHRNB4 4471/4885 |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | CHRNA5, SLC18A3, CHRNA6 | CHRNB2 8/4885CHRNA4 9/4885CHRNB4 11/4885 |
| US-20110086086-A1 | TRANSDERMAL SYSTEM FOR VARENICLINE | CHRNA7, CACNA1G, CACNA1S | CHRNB2 35/4885CHRNA4 31/4885CHRNB4 42/4885 |
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | CHERP, ORAI1, CA2 | CHRNB2 4180/4885CHRNA4 3563/4885CHRNB4 3813/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNB2 9/4885CHRNA4 2/4885CHRNB4 6/4885 |
| US-20110064750-A1 | METHOD AND KIT FOR TREATING NICOTINE ADDICTION | CHAT, NNMT, KIT | CHRNB2 16/4885CHRNA4 14/4885CHRNB4 17/4885 |
| US-20150065708-A1 | COMPOUND JK12A AND PREPARATION THEREOF | GRIK5, GRIK2, GRIK1 | CHRNB2 3346/4885CHRNA4 1761/4885CHRNB4 3354/4885 |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNB2 14/4885CHRNA4 3/4885CHRNB4 13/4885 |
| US-20060057207-A1 | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | CHRNA7, CACNG7, CHRNA9 | CHRNB2 44/4885CHRNA4 26/4885CHRNB4 99/4885 |
| US-10912734-B2 | Depot formulation | CHRNA7, CHRNA1, CHRNB1 | CHRNB2 25/4885CHRNA4 14/4885CHRNB4 28/4885 |
| US-20080026059-A1 | Methods of Reducing Degradant Formation in Pharmaceutical Compositions of Varenicline | NNMT, COMT, BHMT2 | CHRNB2 391/4885CHRNA4 621/4885CHRNB4 890/4885 |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB2 88/4885CHRNA4 82/4885CHRNB4 101/4885 |
| US-20130231388-A1 | (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT | PPOX, OAT, NOTUM | CHRNB2 3198/4885CHRNA4 3100/4885CHRNB4 3341/4885 |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA4 | CHRNB2 16/4885CHRNA4 3/4885CHRNB4 14/4885 |
| US-20190169264-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | GRIK4, GRIK2, GRIK5 | CHRNB2 83/4885CHRNA4 64/4885CHRNB4 78/4885 |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNB2 9/4885CHRNA4 2/4885CHRNB4 6/4885 |
| US-20190350844-A1 | DEPOT FORMULATION | CHRNA7, CHRNA1, CHRNB1 | CHRNB2 25/4885CHRNA4 14/4885CHRNB4 28/4885 |
| US-11602537-B2 | Varenicline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB2 49/4885CHRNA4 41/4885CHRNB4 43/4885 |
| US-20060079707-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | CYP1B1, AZI2, CYP1A1 | CHRNB2 1809/4885CHRNA4 2131/4885CHRNB4 2229/4885 |
| US-20100062046-A1 | POLYMORPHS OF NICOTINIC INTERMEDIATES | NAPRT, NAMPT, NNMT | CHRNB2 22/4885CHRNA4 4/4885CHRNB4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.